1. Home
  2. BEEP vs ACRV Comparison

BEEP vs ACRV Comparison

Compare BEEP & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mobile Infrastructure Corporation

BEEP

Mobile Infrastructure Corporation

HOLD

Current Price

$1.74

Market Cap

78.3M

Sector

Finance

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.62

Market Cap

68.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEEP
ACRV
Founded
2015
2018
Country
United States
United States
Employees
N/A
76
Industry
Blank Checks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.3M
68.5M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
BEEP
ACRV
Price
$1.74
$1.62
Analyst Decision
Buy
Buy
Analyst Count
1
4
Target Price
$6.50
$11.67
AVG Volume (30 Days)
96.1K
449.4K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
$35,075,000.00
N/A
Revenue This Year
$5.77
N/A
Revenue Next Year
$22.12
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$1.20
52 Week High
$4.07
$3.56

Technical Indicators

Market Signals
Indicator
BEEP
ACRV
Relative Strength Index (RSI) 46.32 41.17
Support Level $1.29 $1.38
Resistance Level $2.33 $2.15
Average True Range (ATR) 0.17 0.14
MACD 0.02 -0.04
Stochastic Oscillator 39.08 2.70

Price Performance

Historical Comparison
BEEP
ACRV

About BEEP Mobile Infrastructure Corporation

Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: